The Dark Side of Curing Cancer

Panelists at AACR discuss the health risks that cancer survivors must face.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, NCIAs researchers at this year's American Association for Cancer Research (AACR) meeting presented on promising new treatments for diverse cancer types, one group of experts pointed to the knock-on effects of these therapeutics: long-term health effects of the treatments themselves. “As [a] cure became possible, we started to recognize treatment-related late effects,” said Smita Bhatia, who studies the long-term health and well-being of cancer survivors at City of Hope in Duarte, California.

As of 2012, there were 13.7 million cancer survivors in the U.S.. By 2022, that number is expected to reach 18 million. These patients will face higher risks of secondary cancers, cardiovascular disease, psychosocial issues, and other health problems. “It’s well established that treatment can induce a second malignancy or other late effects,” said Lois Travis from the University of Rochester Medical Center in New York, who noted that the increasing number of cancer survivors is also a significant driver of health-care costs.

Pediatric cancer survivors are of particular interest, because they face “a long duration of future life years in which to manifest some of these complications” said Leslie Robison of St. Jude Children’s Research Hospital. Pediatric cancer survivors are at an up to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours